These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 29925688)

  • 1. Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles.
    Merle NS; Grunenwald A; Rajaratnam H; Gnemmi V; Frimat M; Figueres ML; Knockaert S; Bouzekri S; Charue D; Noe R; Robe-Rybkine T; Le-Hoang M; Brinkman N; Gentinetta T; Edler M; Petrillo S; Tolosano E; Miescher S; Le Jeune S; Houillier P; Chauvet S; Rabant M; Dimitrov JD; Fremeaux-Bacchi V; Blanc-Brude OP; Roumenina LT
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner.
    Merle NS; Paule R; Leon J; Daugan M; Robe-Rybkine T; Poillerat V; Torset C; Frémeaux-Bacchi V; Dimitrov JD; Roumenina LT
    Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6280-6285. PubMed ID: 30850533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis.
    Merle NS; Grunenwald A; Figueres ML; Chauvet S; Daugan M; Knockaert S; Robe-Rybkine T; Noe R; May O; Frimat M; Brinkman N; Gentinetta T; Miescher S; Houillier P; Legros V; Gonnet F; Blanc-Brude OP; Rabant M; Daniel R; Dimitrov JD; Roumenina LT
    Front Immunol; 2018; 9():179. PubMed ID: 29545789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemopexin as an Inhibitor of Hemolysis-Induced Complement Activation.
    Poillerat V; Gentinetta T; Leon J; Wassmer A; Edler M; Torset C; Luo D; Tuffin G; Roumenina LT
    Front Immunol; 2020; 11():1684. PubMed ID: 32849588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical role of C5a in sickle cell disease.
    Vercellotti GM; Dalmasso AP; Schaid TR; Nguyen J; Chen C; Ericson ME; Abdulla F; Killeen T; Lindorfer MA; Taylor RP; Belcher JD
    Am J Hematol; 2019 Mar; 94(3):327-337. PubMed ID: 30569594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis.
    Merle NS; Leon J; Poillerat V; Grunenwald A; Boudhabhay I; Knockaert S; Robe-Rybkine T; Torset C; Pickering MC; Chauvet S; Fremeaux-Bacchi V; Roumenina LT
    Front Immunol; 2020; 11():1772. PubMed ID: 32849636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease.
    Camus SM; De Moraes JA; Bonnin P; Abbyad P; Le Jeune S; Lionnet F; Loufrani L; Grimaud L; Lambry JC; Charue D; Kiger L; Renard JM; Larroque C; Le Clésiau H; Tedgui A; Bruneval P; Barja-Fidalgo C; Alexandrou A; Tharaux PL; Boulanger CM; Blanc-Brude OP
    Blood; 2015 Jun; 125(24):3805-14. PubMed ID: 25827830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease.
    Belcher JD; Chen C; Nguyen J; Milbauer L; Abdulla F; Alayash AI; Smith A; Nath KA; Hebbel RP; Vercellotti GM
    Blood; 2014 Jan; 123(3):377-90. PubMed ID: 24277079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions.
    Merle NS; Boudhabhay I; Leon J; Fremeaux-Bacchi V; Roumenina LT
    Transfus Clin Biol; 2019 May; 26(2):116-124. PubMed ID: 30879901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.
    Arvidsson I; Ståhl AL; Hedström MM; Kristoffersson AC; Rylander C; Westman JS; Storry JR; Olsson ML; Karpman D
    J Immunol; 2015 Mar; 194(5):2309-18. PubMed ID: 25637016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1.
    May O; Merle NS; Grunenwald A; Gnemmi V; Leon J; Payet C; Robe-Rybkine T; Paule R; Delguste F; Satchell SC; Mathieson PW; Hazzan M; Boulanger E; Dimitrov JD; Fremeaux-Bacchi V; Frimat M; Roumenina LT
    Front Immunol; 2018; 9():3008. PubMed ID: 30619356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease.
    Belcher JD; Nguyen J; Chen C; Abdulla F; Conglin R; Ivy ZK; Cummings J; Dudler T; Vercellotti GM
    Transl Res; 2022 Nov; 249():1-12. PubMed ID: 35878790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.
    Frimat M; Tabarin F; Dimitrov JD; Poitou C; Halbwachs-Mecarelli L; Fremeaux-Bacchi V; Roumenina LT
    Blood; 2013 Jul; 122(2):282-92. PubMed ID: 23692858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood.
    Thomas AM; Gerogianni A; McAdam MB; Fløisand Y; Lau C; Espevik T; Nilsson PH; Mollnes TE; Barratt-Due A
    J Immunol; 2019 Sep; 203(6):1571-1578. PubMed ID: 31413105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythrocyte-derived microvesicles amplify systemic inflammation by thrombin-dependent activation of complement.
    Zecher D; Cumpelik A; Schifferli JA
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):313-20. PubMed ID: 24311376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy.
    Roumenina LT; Chadebech P; Bodivit G; Vieira-Martins P; Grunenwald A; Boudhabhay I; Poillerat V; Pakdaman S; Kiger L; Jouard A; Audureau E; Pirenne F; Galactéros F; Frémeaux-Bacchi V; Bartolucci P
    Am J Hematol; 2020 May; 95(5):456-464. PubMed ID: 31990387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythrocyte and plasma oxidative stress appears to be compensated in patients with sickle cell disease during a period of relative health, despite the presence of known oxidative agents.
    Detterich JA; Liu H; Suriany S; Kato RM; Chalacheva P; Tedla B; Shah PM; Khoo MC; Wood JC; Coates TD; Milne GL; Oh JY; Patel RP; Forman HJ
    Free Radic Biol Med; 2019 Sep; 141():408-415. PubMed ID: 31279092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.
    Gu H; Fisher AJ; Mickler EA; Duerson F; Cummings OW; Peters-Golden M; Twigg HL; Woodruff TM; Wilkes DS; Vittal R
    FASEB J; 2016 Jun; 30(6):2336-50. PubMed ID: 26956419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases.
    Vinchi F; De Franceschi L; Ghigo A; Townes T; Cimino J; Silengo L; Hirsch E; Altruda F; Tolosano E
    Circulation; 2013 Mar; 127(12):1317-29. PubMed ID: 23446829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective regulation of complement by the sickle erythrocyte: evidence for a defect in control of membrane attack complex formation.
    Test ST; Woolworth VS
    Blood; 1994 Feb; 83(3):842-52. PubMed ID: 7507737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.